Department of Heart Surgery, Service de chirurgie cardiaque, Nouvel Hôpital Civil, 67000 Strasbourg, France.
Eur J Cardiothorac Surg. 2011 Sep;40(3):e112-7. doi: 10.1016/j.ejcts.2011.04.005. Epub 2011 May 18.
To present the analyzed results on mechanical circulatory support (MCS) collected over a 7-year period, from 2000 to 2006, in France.
A cohort of 520 patients was analyzed. Mean age was 43.7 ± 13.6 years. The main causes of cardiac failure were ischemic cardiomyopathy (39%), idiopathic dilated cardiomyopathy (41.3%), or myocarditis (6.4%). Bridge to transplantation was indicated in 87.8% of patients, bridge to recovery in 9%, while destination therapy was proposed in 3.2% of patients.
For patients in cardiogenic shock or advanced heart failure undergoing device implantation as bridge to transplantation or recovery (n=458), overall mortality was 39% (n=179). The main causes of mortality under MCS were multi-organ failure (MOF) (57.4%), neurological events (14.1%), or infections (11.9%). Heart transplantation was performed in 249 (54.3%) patients. The main causes of death following heart transplantation were primary graft failure (22.4%), MOF (14.3%), neurological event (14.3%), or infection (10.2%). Long-term survival in transplanted patients was 75 ± 2.8% at 1 year and 66 ± 3.4% at 5 years.
MCS is an essential therapeutic tool to save the life of young patients with cardiogenic shock or advanced cardiac failure. Early MCS implantation and the availability of a device that is adapted to the patient's clinical status are prerequisites for reducing overall mortality rates.
呈现 2000 年至 2006 年期间法国收集的为期 7 年的机械循环支持(MCS)分析结果。
对 520 例患者进行了分析。平均年龄为 43.7 ± 13.6 岁。心力衰竭的主要病因是缺血性心肌病(39%)、特发性扩张型心肌病(41.3%)或心肌炎(6.4%)。87.8%的患者被建议桥接移植,9%的患者桥接恢复,3.2%的患者被建议采用终末期治疗。
对于因心源性休克或晚期心力衰竭而接受器械植入以桥接移植或恢复的患者(n=458),总体死亡率为 39%(n=179)。MCS 下死亡的主要原因是多器官衰竭(MOF)(57.4%)、神经系统事件(14.1%)或感染(11.9%)。249 例(54.3%)患者接受了心脏移植。心脏移植后死亡的主要原因是原发移植物衰竭(22.4%)、MOF(14.3%)、神经系统事件(14.3%)或感染(10.2%)。移植患者的 1 年和 5 年长期存活率分别为 75 ± 2.8%和 66 ± 3.4%。
MCS 是挽救心源性休克或晚期心力衰竭年轻患者生命的重要治疗工具。早期 MCS 植入和拥有适合患者临床状况的器械是降低总体死亡率的前提。